Many thanks to the participants, and especially the speakers: Catherine Verfaillie (KULeuven (host)), Francesca Pistollato (EURLECVAM (invited speaker)), Annemie Ribbens (icometrix), Sebastiaan Engelborghs (UAntwerpen), Gerard Griffioen (reMYND), Jacco Briede and Rob Schlooz (UMaastricht) and Erwin L Roggen (ToxGenSolutions).
The presentations will soon be available on toxgensolutions.eu.
ToxGenSolutions BV invites applications for a position as experienced researcher, starting January 1, 2019.
You see you self as a researcher at a spin-off company based at the University of Maastricht with an ambition to expand. The research field is Neurodegeneration of the human brain, with focus on Alzheimer’s Disease (AD).
The successful candidate will participate in an AD project supported by EU Interreg. Vlaanderen – Nederland, het Nederlands Ministerie van Economische Zaken, de Provincie Nederlands Limburg, Vlaams Agentschao Innoveren en Ondernemen (VLAIO) and the Provinces of Antwerpen and Vlaams Brabant.
- Experimental planning of the project, problem solving and assuring compliance with the timelines of the project.
- Laboratory work within the field of microRNA detection.
- Performance of differential (epi-)genomics and pathway analyses.
- Handling and reporting of experimental data.
- Preparing microRNA profiles with diagnostic value for the market.
Applicants should have a PhD degree in (epi)genomics or equivalent with several years of experience.
- You have experience with and enjoy laboratory work.
- You have hands-on experience with state-of-the-art (epi-)genomics technologies.
- Experience in bioinformatics will be considered an advantage.
- You communicate fluently in English.
- You can work with deadlines and pressure.
- You are flexible, enthusiastic and responsible, with team spirit and excellent collaboration skills.
ToxGenSolutions BV offers a competitive scientific environment with the ambition to build a self-sustainable company applying front-edge non-animal toxicogenomics approaches on human health problems to provide the customer with genetic biomarker fingerprints for application in novel more accurate methods for diagnosis, novel tools for follow-up of disease progression or response to treatment in humans, and novel drug development.
The appointment will be based on the current wage scales that are applied by the University of Maastricht. The position is for two years.
You can read more about ToxGenSolutions BV on www.toxgensolutions.eu.
Please submit your application no later than December 10, 2018 (Local time). Applications and enclosures received after the deadline will not be considered.
Applications must be submitted as one PDF file containing all your materials in English. The file must include:
- Application (cover letter)
- Diploma (MSc)
All interested candidates irrespective of age, gender, disability, race, religion or ethnic background are encouraged to apply.
The project ‘Herinneringen’ (‘Memories’) is about to finish the first year of its search for a cost-effective and minimally invasive method allowing for accurate diagnosis of (sporadic) Alzheimer’s disease (AD) before significant damage to the brain has occurred. You are hereby cordially invited to the first annual meeting on November 23th 2018 in building ON1 at the katholieke University Leuven (Herestraat 49, Leuven). Participation is free but registrations via the project web site (Menu, Contact) is required for practical reasons. The program can be downloaded from the same web site. Francesca Pistollato from the European Reference Laboratory – European Center for validation of Alternative methods to Animal Testing (EURL-ECVAM) will address the current challenges met by traditional AD research, and the need for the paradigm shift that forms the basis of the project ‘‘Herinneringen’ (‘Memories’). The project partners will present an overview of the different activities that are planned to meet the final goal, and progress will be reported where relevant. Special attention will be given to (i) the selection of the external risk factors for sporadic AD; (ii) the cell-based methods for identification of molecular and cellular processes that may be involved in the onset and early development of AD-related processes; (iii) the strategies to scientifically validated the human relevance of the identified potential biomarkers. See you November 23th.